Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00820222
- Locations
- 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT00790816
- Locations
- 🇪🇸
Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT00777101
- Locations
- 🇿🇦
The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa
🇹🇭Division of Medical Oncology, Department of Medicine, Bangkok-noi, Bangkok, Thailand
🇬🇧Broomfield Hospital, Chelmsford, Essex, United Kingdom
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT00759642
- Locations
- 🇺🇸
Truman Medical Center, Kansas City, Missouri, United States
🇺🇸Cotton-O-Neil Cancer Center (Stormont Vail Health Care), Topeka, Kansas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Phase II Neoadjuvant in Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00756470
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 16
- Registration Number
- NCT00754702
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
Lapatinib and Circulating Tumor Cells in Breast Cancer
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 20
- Registration Number
- NCT00694252
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Greece
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT00680901
- Locations
- 🇺🇦
Novartis Investigative Site, Zaporizhzhia, Ukraine
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT00650910
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00632489
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.